- Home
- BPOP vs AXSM Comparison
BPOP vs AXSM Comparison
Compare BPOP & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPOP | AXSM |
|---|---|---|
| Founded | 1893 | 2012 |
| Country | United States | United States |
| Employees | 9406 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 9.0B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BPOP | AXSM |
|---|---|---|
| Price | $130.67 | $158.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | $148.60 | ★ $209.18 |
| AVG Volume (30 Days) | 472.9K | ★ 504.5K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.33 | $58.34 |
| Revenue Next Year | $6.02 | $54.30 |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $78.23 | $86.99 |
| 52 Week High | $149.31 | $191.50 |
Technical Indicators
Market Signals| Indicator | BPOP | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 39.79 |
| Support Level | $123.14 | $153.37 |
| Resistance Level | $149.23 | $169.11 |
| Average True Range (ATR) | 3.57 | 3.97 |
| MACD | -0.64 | -0.23 |
| Stochastic Oscillator | 39.09 | 35.14 |
Price Performance
Historical ComparisonAbout BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.